Can Mounjaro Help with Sleep Apnoea — and Is It the Right Decision for You?

The decision you are actually facing

Most people who land on this page are already managing obstructive sleep apnoea (probably with a CPAP machine) and are wondering whether treating the underlying weight is a route to real improvement, or even to needing less reliance on the device. That is a reasonable clinical question, and the evidence is now substantial enough to take seriously.

Obstructive sleep apnoea occurs when the upper airway collapses during sleep, typically because soft tissue and fat deposits around the throat reduce the space available to breathe. Weight loss reliably reduces that anatomical pressure. The question is how much weight loss, and whether a medicine like tirzepatide can deliver enough of it to move the needle on apnoea severity.

The answer is that it can, in clinical trials, it did so materially. But the decision about whether to start tirzepatide is never just about the apnoea. A prescriber will look at your BMI, your other health conditions, any medicines you take, and your overall suitability. Sleep apnoea is one piece of a broader clinical picture, not a guaranteed entry ticket. Our tirzepatide overview sets out what the treatment involves from the start.

What the trial evidence says about sleep apnoea specifically

The SURMOUNT-OSA programme was a pair of phase 3 randomised controlled trials designed specifically to assess tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity. One group used CPAP alongside tirzepatide; the other did not use CPAP. Both trials ran for 52 weeks.

Across both trials, tirzepatide produced large reductions in the apnoea-hypopnoea index (AHI) (the standard measure of how many times per hour breathing is disrupted) compared with placebo. In the non-CPAP group, AHI fell by roughly 25 events per hour more than in the placebo group. Participants also lost around 20% of body weight on average. Secondary outcomes including hypoxic burden, patient-reported sleep quality and blood pressure all moved favourably.

These results were published in the New England Journal of Medicine as part of the broader SURMOUNT evidence base and informed NICE's appraisal of tirzepatide. How Mounjaro acts on sleep apnoea is covered in more detail if you want to understand the mechanism behind those numbers, and you can also read about how tirzepatide helps with sleep apnea for a closer look at the pharmacological pathway involved.

One thing worth noting: the trials enrolled people with obesity and obstructive sleep apnoea. Central sleep apnoea (which has a neurological rather than anatomical cause) is a different condition, and the evidence here does not straightforwardly transfer. If you are unsure which type you have, your GP or sleep clinic will have that on record.

Eligibility: does sleep apnoea get you across the threshold?

Under Mounjaro's UK licence, tirzepatide is approved for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition. Obstructive sleep apnoea is explicitly one of those qualifying conditions, and if you are researching whether Mounjaro is suitable for apnea, the short answer is that this combination can meet the licensed criteria where your BMI sits between 27 and 29.9.

On the NHS, access to tirzepatide through NICE's appraisal (TA1026) follows a separate, phased rollout with stricter thresholds. The NICE TA1026 recommendations set out who qualifies now and in future phases. For many people, that route involves waiting.

Through a private regulated pharmacy such as nume, the licensed eligibility criteria apply directly, no referral needed, no waiting list. A prescriber reviews your consultation the same day; a real clinician reads it, not an automated system. If you have been looking into using Mounjaro for sleep apnea specifically, that context matters and our prescribers will take it into account when reviewing your case. You can check your eligibility with a free consultation to find out whether tirzepatide is clinically suitable for you.

Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, your prescriber will apply these correctly based on the information you provide.

Practical considerations before you decide

A few things are worth thinking through before starting any weight-loss treatment in the context of sleep apnoea.

First, tirzepatide is not a replacement for CPAP while you are still at your starting weight. The two approaches work in parallel during the treatment period; decisions about adjusting CPAP settings should be made with your sleep team or GP as your weight changes, not unilaterally.

Second, the weight loss with tirzepatide is dose-dependent and takes time. Treatment starts at 2.5mg (a tolerability dose designed to help your body adjust) and the prescriber titrates upward over several months. Meaningful apnoea improvement tends to follow meaningful weight loss, which builds over the course of treatment rather than arriving immediately. Some people find that reassuring; others want faster relief and should keep CPAP running in the interim.

Third, side effects are predominantly gastrointestinal: nausea, changes in appetite, and sometimes loose stools, most commonly in the first weeks after a dose change. The NHS tirzepatide medicines page lists what to watch for and when to get medical help. Our prescribers and aftercare team are available seven days a week if questions come up after you start.

For a broader look at what this medicine involves day to day, our Mounjaro overview covers storage, administration and what to expect across the treatment period. If cost is a consideration, our weight-loss treatment page sets out what is included in a single transparent price, consultation, prescription, next-working-day delivery and aftercare, with no subscription.